Johnson & Johnson Completes Acquisition of Abiomed

Johnson & Johnson to Acquire Ambrx Biopharma in ~$2 Billion All-Cash Deal

January 8, 2024

Pharmaceuticals

Johnson & Johnson announced it has entered into a definitive agreement to acquire Ambrx Biopharma in an all-cash merger transaction valued at about $2 billion (about $1.9 billion net of estimated cash acquired). The deal is intended to add Ambrx’s proprietary synthetic biology and ADC (antibody-drug conjugate) technology platform and its clinical and preclinical oncology pipeline to J&J’s targeted oncology therapeutics efforts.

Johnson & Johnson to Acquire V-Wave for Up to $1.7 Billion

October 9, 2024

Healthcare Services

Johnson & Johnson (J&J) entered into a definitive agreement to acquire V-Wave, a privately held heart-failure treatment company, for an upfront payment of $600 million and potential regulatory/commercial milestone payments up to about $1.1 billion (total up to ~$1.7 billion). The acquisition is expected to close before the end of 2024, and will add V-Wave’s Ventura Interatrial Shunt implant technology to the J&J MedTech Cardiovascular portfolio.

Haemonetics Acquires Cardiva Medical

January 20, 2021

Medical Devices

Haemonetics Corporation agreed to acquire Cardiva Medical, Inc., a privately-held maker of vascular closure systems based in Santa Clara, California, for $475 million upfront and up to $35 million in contingent consideration. The acquisition expands Haemonetics' hospital portfolio and its presence in the interventional cardiology and electrophysiology markets and is expected to be accretive to revenue growth.

Abbott Acquires Cardiovascular Systems, Inc.

February 8, 2023

Medical Devices

Abbott entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (CSI), a medical device company focused on atherectomy systems for treating peripheral and coronary artery disease. Under the terms of the deal, CSI stockholders will receive $20 per share, for an expected total equity value of approximately $890 million.

Johnson & Johnson (Ethicon) Acquires Auris Health

April 1, 2019

Medical Devices

Johnson & Johnson, through its surgical devices unit Ethicon, completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash with up to $2.35 billion in contingent payments. The deal brings Auris' Monarch robotic bronchoscopy platform and related digital surgery capabilities into J&J's medical devices portfolio to accelerate capability expansion in digital and robotic surgery, particularly for lung cancer diagnosis and intervention.

Johnson & Johnson to Acquire Shockwave Medical for $13.1 Billion

April 5, 2024

Healthcare Services

Johnson & Johnson (JNJ) entered into a definitive agreement to acquire all outstanding shares of Shockwave Medical for $335.00 per share in cash, implying an enterprise value of about $13.1 billion. The deal expands J&J MedTech’s cardiovascular intervention portfolio—adding Shockwave’s intravascular lithotripsy (IVL) technology for calcified coronary and peripheral artery disease.